Agmatine for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Agmatine for Health & Longevity

Created on 06/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Agmatine is an inexpensive, low-burden but experimental supplement made from arginine. Consistent animal data show calming of nerve signaling, brain-cell protection, and pain relief, but human proof is thin. The best human signal is relief of nerve-related back pain; mood and brain benefits remain unproven. Short use seems well tolerated; long-term safety is unknown. (Full Review)

Protocol

Studied Clinical Dose
2.67 g/day
Agmatine sulfate; dose used in the placebo-controlled pain trial, taken for defined periods of weeks.
Nootropic/Lower Range
250 mg–1.6 g/day
For mood and cognitive use; often start at 250–500 mg and titrate over 1–2 weeks.
Timing & Dosing
Empty stomach, split 2–3×
Away from protein to maximize absorption; short ~2 h half-life favors divided daily doses.
Time to effect
Neuropathic Pain
~2 weeks
Controlled trial dosed over about two weeks with continuous improvement.
Mood/Nootropic
Days to weeks
Where reported, effects described over days to weeks; no rapid single-dose human effect established.

Benefits

Contraindications
  • Pregnant or breastfeeding individuals
  • Clinically low blood pressure or symptomatic hypotension
  • Poorly controlled diabetes on intensive glucose-lowering therapy
  • Significant kidney impairment
    •
Key Interactions
  • Antihypertensive drugs (alpha-2 agonists, ACE inhibitors, ARBs, beta-blockers)
  • Glucose-lowering drugs (insulin, sulfonylureas, metformin)
  • Sedatives and central-nervous-system agents (benzodiazepines, opioids)
  • OTC blood-pressure-active antihistamine/decongestant products
  • High-dose arginine or protein (lysine, ornithine)
  • Blood-pressure- or blood-sugar-lowering supplements (magnesium, potassium, CoQ10, beetroot/nitrate, berberine, chromium, alpha-lipoic acid)
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: Gastrointestinal upset
    •
  • Low: Blood pressure lowering; blood sugar lowering
    •
  • Speculative: Effects during pregnancy and breastfeeding; long-term and high-dose unknowns; additive sedation or mood effects
    •

Monitoring

Marker Target Why
Resting blood pressure ~110–125 / 70–80 mmHg Detects additive hypotension from agmatine
Fasting glucose 75–90 mg/dL Detects additive glucose lowering
HbA1c <5.4% Tracks longer-term glucose effect if used chronically
eGFR (kidney function) >90 mL/min/1.73 m² Agmatine is renally cleared; flags reduced clearance
Symptom/pain score (e.g., VAS) Lower than baseline Defines treatment success for the target indication

Cadence: Baseline; re-check at ~1–2 weeks after starting and after any dose increase, then periodically (every 1–2 months) while continuing use.

Qualitative Assessment

  • Reduction in neuropathic or chronic pain intensity and frequency
  • Improvement in mood, stress resilience, or anxiety levels
  • Subjective changes in focus, mental clarity, or cognitive ease
  • Sleep quality and ease of falling asleep
  • Absence of gastrointestinal upset, lightheadedness, or other side effects
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.